Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 2,120 trials

IgG4-Related Disease: Obexelimab Treatment Study

We are studying a new medication, obexelimab, for people with IgG4-related disease to see if it helps prevent flare-ups after steroid treatment. We will also check how safe and well-tolerated it is for patients.

IgG4-Related Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

Diabetic Neuropathic Pain: Incobotulinumtoxin-A Injections

We are studying whether injections of incobotulinumtoxin-A can help relieve pain in people with diabetic neuropathic pain in their lower extremities. The trial will also look at how this treatment affects daily activities and overall quality of life.

Diabetic Peripheral Neuropathic Pain6-12 monthsEfficacy phase (II)Standard MedicinesDiabetologyEndocrinologyNeurology

HER2+ Breast Cancer: Tucatinib with Oral Etoposide and Trastuzumab

We are studying a new treatment combining tucatinib, oral etoposide, and trastuzumab for patients with metastatic HER2+ breast cancer who have not responded to prior therapies. The goal is to see if this combination improves treatment outcomes and safety.

Metastatic HER2+ Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Geographic Atrophy: JNJ-81201887 Treatment Study

We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.

Geographic Atrophy>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteOphthalmology

Heart Attack Treatment: Methylprednisolone Study

We are investigating whether a steroid given before hospital treatment can reduce heart damage in patients with a heart attack. This study aims to improve heart function and decrease inflammation after the event.

Heart Attack1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Morphine Study in Obesity and Sleep Apnea Patients

We are investigating how obesity and obstructive sleep apnea influence the effects of morphine for pain relief. This research aims to improve pain management for patients, especially those having bariatric surgery.

Obesity Surgery>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementEndocrinologyInternal MedicineOrthopedics and TraumatologyOtolaryngologyPsychiatry

Multiple Myeloma: Anti-BCMA CAR T Cell Therapy

We are studying a new CAR T cell treatment for patients with relapsed or refractory Multiple Myeloma. The trial aims to evaluate its safety and effectiveness in improving patient outcomes.

Relapsed/Refractory Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Myeloid Leukemia: New Treatments for Children and Adolescents

We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyPediatrics

Eosinophilic Gastritis: Dupilumab Treatment Study

We are investigating how well dupilumab works for adults and adolescents with eosinophilic gastritis, with or without eosinophilic duodenitis. The study will also look at the safety and side effects of this treatment.

Eosinophilic Gastritis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Prostate Cancer: Neoadjuvant Treatment with [177Lu]Lu-PSMA-617

We are studying a new method of delivering a targeted treatment for men with high-risk prostate cancer before surgery. The goal is to evaluate its safety and how well it works compared to standard approaches.

High-Risk Prostate Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Achilles Tendinopathy: NGI226 Microparticles Study

We are investigating the safety and effects of NGI226 microparticles for patients with Achilles tendinopathy. This study aims to see if it helps restore tendon strength compared to a placebo.

Achilles Tendinopathy6-12 monthsEfficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Type 1 Diabetes: INVITED Trial on Flu Vaccine

We are studying whether influenza vaccination can help protect insulin-producing cells in individuals with early type 1 diabetes. This research aims to find new ways to support diabetes management.

Type 1 Diabetes>2 yearsEfficacy phase (II)Standard MedicinesEndocrinologyInfectious Diseases

Esophageal Cancer Treatment: The NEEDS Trial

We are comparing two treatment methods for operable esophageal squamous cell carcinoma to see which may help patients survive longer. The study also examines quality of life and other health impacts during and after treatment.

Locally Advanced Esophageal Squamous Cell Carcinoma≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Melanoma Treatment: Nivolumab + Relatlimab Injection Study

We are comparing a new way to give a combination treatment for advanced melanoma to see if it works as well as the traditional method. This study is for people who have not yet been treated for their melanoma.

Metastatic MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Venous Thromboembolism: Anticoagulant Therapy Study

We are studying whether full-dose anticoagulant therapy alone is safer and more effective than combining it with antiplatelet therapy for patients with acute VTE. This research aims to improve treatment options for those already taking antiplatelets.

Deep Venous Thrombosis and Pulmonary Embolism>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine